Skip to main content
. Author manuscript; available in PMC: 2011 Jun 1.
Published in final edited form as: Cell Stem Cell. 2010 Dec 3;7(6):682–693. doi: 10.1016/j.stem.2010.11.013

Figure 6. Bmi-1 inhibition protects primary prostate cells from hyperplasia driven by FGF10 signaling.

Figure 6

(A) Schematic shows experimental approach. (B) Average weight of 6 scrambled shRNA/FGF10 UGSM and Bmi-1 shRNA/FGF10 UGSM grafts each from 2 experiments. (C) TI (top) and RFP fluorescence images (bottom) of scrambled shRNA/FGF10 (left) and Bmi-1 shRNA/FGF10 (right) grafts. (D) H&E sections show representative tubules from Bmi-1 and scrambled shRNA infected grafts (top). Fluorescence images show representative tubules and their infection status (red) from Bmi-1 and scramble shRNA infected tubules. Bars=200μm. (E) Average percentage of hyperplastic and normal appearing RFP+ tubules calculated from 10 representative sections from 3 grafts of each condition, represented as mean +/− SEM. (F) H&E and fluorescence images show viral infection status (red), AR (green), p63 (green), and Ki67 (green) staining of a Scrambled shRNA infected region(red) (top) and a Bmi-1 shRNA infected tubule (red) surrounded by non-infected epithelium (non-colored) (bottom). Bars=100μm. See also Figure S7A.